Studying congenital disorders of glycosylation to understand their causes and symptoms
Studies people with congenital disorders of glycosylation to learn more about these conditions.
Key facts
- Who runs it
- National Human Genome Research Institute (NHGRI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 7 Mar 2014
- Expected to end
- 1 Dec 2030
- Type of study
- Observational
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a known or suspected congenital disorder of glycosylation (CDG), an inherited problem attaching sugars to body molecules. Relatives of patients with known CDG can also join to give samples for carrier testing and as controls.
- Age
- 1 Month to 80 Years. Children 1 month to 2 years are seen as outpatients or by telehealth.
- Sex
- All sexes
- Disease stage
- Known or suspected CDG. People over 2 years are admitted only if medically stable and needing a hospital stay for diagnosis.
- Biomarker or test result
- Suspected CDG based on biochemical tests, or confirmed CDG based on enzymatic or molecular tests.
Main reasons for not taking part
- Babies under 1 month of age
- People over 2 years who are medically unstable and do not need admission for diagnosis
- Pregnant women
- Newborns
The registry criteria, word for word
Show all 4 criteriaShow less
Who cannot take part
- Participants under 1 month of age will not be seen at the NIH Clinical center because care is more readily proffered to older individuals at the Clinical Center
- Participants over two years of age will not be admitted if they are medically unstable and do not require admission to the Clinical Center for diagnosis
- Pregnant women and newborns are excluded
Other criteria
- INCLUSION CRITERIA:; Participants 1 month or older will have been or will be referred to this protocol with a known or suspected CDG. Participants over two years of age will be admitted only if they are medically stable and require admission to the Clinical Center for diagnosis. One or more probands may be admitted to the NIH Clinical Center for investigation as well as carrier family members; Some participants will be relatives of patients with known CDG's, and their specimens will be obtained for the purpose of heterozygote testing and to serve as controls to help diagnose the proband. Participants may be seen as inpatients, outpatients or via Telehealth. In some cases, biologic samples may be obtained remotely and sent to the Gahl lab
This trial is currently available in United States.
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Lynne Wolfe, M.S.Taking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
- Proteins, fats, and other molecules are the body s building blocks. Many of these molecules must have sugars, or chains of sugars, attached to work properly. People with congenital disorders of glycosylation (CDGs) cannot attach these sugars or sugar chains properly. A child or adult with a CDG can have symptoms in different parts of the body, including brain, nerves, muscles, liver, and immune system. Researchers want to learn more about these diseases to understand better what is causing the problems.
Objective:
- To learn more about CDGs.
Eligibility:
- People 1 month to 2 years old may be seen as outpatients or by telehealth. Patients 2-80 years with CDG or suspected to have a CDG may be seen under this protocol as inpatients, outpatients or by teleheath.
Design:
* CDG participants may be seen as inpatients, outpatients or by teleheath. Inpatient stays may last 2-5 days. * They will have:-Medical history and physical exam. They will answer questions about their CDG. * Blood taken several times. Their skin will be numbed, then a needle will take blood from an arm vein. * Samples taken of their skin, urine, and maybe stool and spinal fluid. * Photos taken of their whole body. They can wear underwear and cover their eyes. * Brain MRI. They will lie on a table that slides in and out of a metal cylinder. The scanner makes loud knocking noises so they can wear earplugs. * Abdomen ultrasound. Sound waves take images of the body from the outside. * Hand/wrist X-rays for young patients. They may have a full-body X-ray. * DEXA bone density scan. Participants will lie on a table under a scanner. * Echocardiogram and electrocardiogram for heart activity. Pads are stuck on the skin and the electrical activity of the heart is recorded. * Tests of hearing, thinking, motor skills, and speech. * Children participants may have tests done under sedation if it will benefit them directly. * CDG participants may have other procedures during their visit. They may have follow-up visits every year.
The group in the trial
- CDG
Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation and Deglycosylation
- Plain-language title
- Studying congenital disorders of glycosylation to understand their causes and symptomsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2026